Sinovac Biotech, Long Term Debt

Sinovac Biotech, posts a long-term debt of $270M as of December 2025. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

Long-Term Debt is one piece of Sinovac Biotech,'s financial statement story. At $270M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SVA's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sinovac Biotech,'s other metric pages and overview cover the third.

Judging Sinovac Biotech, against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term debt easier to interpret. Start with $270M here, then scan peer and history charts to see if the gap is persistent.